Form 4: Aptose Biosciences Inc. Form 4 Filing Analysis

Warren Whitehead reports changes in beneficial ownership of Aptose Biosciences Inc. common shares and stock options, reflecting a business arrangement agreement.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership of securities for Warren Whitehead, a former director of Aptose Biosciences Inc.
• The transactions occurred on June 30, 2026, and are related to a business arrangement agreement between Aptose Biosciences Inc. and Hammi Pharmaceuticals Co. Ltd.
• As part of this agreement, a subsidiary of Hammi acquired all outstanding shares of Aptose Biosciences Inc. at C$2.41 per share.
• Warren Whitehead disposed of 33 common shares, with the price converted from Canadian dollars to USD using an exchange rate of C$1.4 = US$1.00, resulting in a US$1.72 price.
• The filing also details various stock options held by Whitehead, including Director Stock Options and Director Option Grants, with different exercise prices and grant dates.
• These options are subject to adjustments due to previous reverse stock splits.
• The earliest transaction date noted is June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on past transactions related to an acquisition and does not offer new operational or financial performance data.

Positives

• The filing clearly outlines the disposition of securities as part of a pre-approved business arrangement, indicating a structured and transparent process.
• The acquisition price of C$2.41 per share by Hammi Pharmaceuticals Co. Ltd. provides a clear valuation benchmark for the transaction.

Negatives

• The filing indicates a disposition of securities, which, in the context of a former director, suggests a cessation of direct involvement or ownership following the acquisition.
• The conversion of the share price from CAD to USD at a specific exchange rate (C$1.4 = US$1.00) might not reflect the exact market rate at the time of the transaction, potentially impacting the perceived value.

Risks

• The filing mentions that stock options are subject to adjustment due to previous reverse stock splits (1:30 on 2/25/25 and 1:15 on 6/6/2023), which can complicate the understanding of the actual number of shares and exercise prices.
• The business arrangement agreement with Hammi Pharmaceuticals Co. Ltd. implies a change in control or acquisition, which can introduce integration risks and uncertainties for remaining stakeholders if not managed effectively.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from management regarding future business operations, as it primarily reports past transactions related to an acquisition.

Management Comments

• The filing notes that options are subject to adjustment as a result of the issuer's reverse stock splits.
• The disposition of securities was made pursuant to a board, shareholder, and court-approved business arrangement agreement.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting changes in beneficial ownership by insiders, often occurring during significant corporate events like acquisitions or divestitures. The transaction described here, involving the acquisition of Aptose Biosciences Inc. by a subsidiary of Hammi Pharmaceuticals Co. Ltd., is a common M&A activity within the biotechnology sector.

Management Changes

Legal Proceedings

• The business arrangement agreement was approved by the board, shareholders, and court.

Related Party Transactions

• The filing details transactions involving Warren Whitehead, a former director, in relation to the acquisition of Aptose Biosciences Inc. by Hammi Pharmaceuticals Co. Ltd.

Stakeholder Impact

• Shareholders of Aptose Biosciences Inc. have received C$2.41 per share as part of the acquisition.
• Former directors and officers, like Warren Whitehead, have reported changes in their beneficial ownership of securities.
• Employees may experience changes in employment terms or roles following the acquisition by Hammi Pharmaceuticals Co. Ltd.

Next Steps

• The acquisition of Aptose Biosciences Inc. by a subsidiary of Hammi Pharmaceuticals Co. Ltd. is complete.
• Further filings may be expected from former insiders regarding their holdings post-acquisition.

Key Dates

Keywords

Form 4, Beneficial Ownership, Aptose Biosciences Inc., Warren Whitehead, Stock Options, Business Arrangement, Acquisition, Securities, Director, Hammi Pharmaceuticals